BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1:2. [PMID: 30288305 DOI: 10.1186/s41124-016-0011-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Papatheodoridis GV, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, Anagnostou O, Tsoulas C, Hatzakis A, Dalekos GN. Aiming towards hepatitis C virus elimination in Greece. Ann Gastroenterol. 2019;32:321-329. [PMID: 31263353 DOI: 10.20524/aog.2019.0375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
3 Roncero C, Littlewood R, Vega P, Martinez-Raga J, Torrens M. Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. Eur J Gastroenterol Hepatol 2017;29:629-33. [PMID: 28230562 DOI: 10.1097/MEG.0000000000000855] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
4 Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J 2019;16:32. [PMID: 31072401 DOI: 10.1186/s12954-019-0303-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Barré T, Mercié P, Marcellin F, Esterle L, Duvivier C, Teicher E, Bureau M, Chas J, Salmon-Céron D, Sogni P, Carrieri MP, Wittkop L, Protopopescu C; ANRS CO13 HEPAVIH Study Group. HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). AIDS Behav 2021. [PMID: 33903998 DOI: 10.1007/s10461-021-03277-x] [Reference Citation Analysis]
7 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
8 Gilman M, Littlewood R. A Pilot Survey of Hepatitis C Knowledge and Awareness of Novel Treatment Options Engaged with Narcotics Anonymous: How Can Group Therapy Help? Journal of Groups in Addiction & Recovery 2017;12:37-44. [DOI: 10.1080/1556035x.2016.1258684] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV; Hep-Nordic Study Group. Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS One 2018;13:e0190146. [PMID: 29381697 DOI: 10.1371/journal.pone.0190146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hashim A, O'Sullivan M, Williams H, Verma S. Developing a community HCV service: project ITTREAT (integrated community-based test - stage - TREAT) service for people who inject drugs. Prim Health Care Res Dev 2018;19:110-20. [PMID: 29199921 DOI: 10.1017/S1463423617000731] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Barré T, Nishimwe ML, Protopopescu C, Marcellin F, Carrat F, Dorival C, Delarocque‐astagneau E, Larrey D, Bourlière M, Petrov‐sanchez V, Simony M, Pol S, Fontaine H, Carrieri P; the ANRS/AFEF Hepather study group. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort). J Viral Hepat 2020;27:1473-83. [DOI: 10.1111/jvh.13380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Robaeys G, Christensen S, Lucidarme D, Arain A, Bruggmann P, Kunkel J, Keim S, Jäkel M, DeMasi R, Liu C, Lonjon-Domanec I, Foster GR. Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study. Infect Dis Ther 2017;6:265-75. [PMID: 28477061 DOI: 10.1007/s40121-017-0158-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Lee SS, Crofts N, Hung CC. Macro-efforts for the micro-elimination of hepatitis C targeting people who inject drugs. Int J Infect Dis. 2019;85:141-142. [PMID: 31229938 DOI: 10.1016/j.ijid.2019.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Barré T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). Addiction 2020;115:573-82. [PMID: 31595554 DOI: 10.1111/add.14820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
15 Marcellin F, Jaquet A, Lazarus JV, Molina P, Carrieri P. Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play. Semin Liver Dis 2021;41:109-16. [PMID: 32851613 DOI: 10.1055/s-0040-1716343] [Reference Citation Analysis]
16 Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol 2021;27:246-56. [PMID: 33317245 DOI: 10.3350/cmh.2020.0230] [Reference Citation Analysis]
17 Fernàndez-López L, Baros S, Niedźwiedzka-Stadnik M, Staneková DV, Rosińska M, Simic D, Jovanoic V, Hábeková M, Takáčová M, Wawer I, Wysocki P, Conway A, Klavs I, Casabona J. Integration of community-based testing data into national HIV surveillance in Poland, Serbia and Slovakia within the framework of INTEGRATE project. BMC Infect Dis 2021;21:800. [PMID: 34517839 DOI: 10.1186/s12879-021-06498-6] [Reference Citation Analysis]
18 Molinaro S, Resce G, Alberti A, Andreoni M, D′egidio PPF, Leonardi C, Nava FA, Pasqualetti P, Villa S. Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. Drug Alcohol Rev 2019;38:644-55. [DOI: 10.1111/dar.12978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Salmon D, Mondelli MU, Maticic M, Arends JE; The ESCMID Study Group for Viral Hepatitis. The benefits of hepatitis C virus cure: Every rose has thorns. J Viral Hepat 2018;25:320-8. [DOI: 10.1111/jvh.12823] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
20 Torrens M, Soyemi T, Bowman D, Schatz E. Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. BMC Infect Dis 2020;20:702. [PMID: 32972393 DOI: 10.1186/s12879-020-05426-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Surey J, Menezes D, Francis M, Gibbons J, Sultan B, Miah A, Abubakar I, Story A. From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J Antimicrob Chemother 2019;74:v17-23. [PMID: 31782500 DOI: 10.1093/jac/dkz452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]